Search

Alex Callo represents clients in high stakes intellectual property litigation, with a specific focus on complex pharmaceutical patent litigation under the Hatch-Waxman Act. His experience includes drafting motions and pleadings, research, and analyzing discovery. Alex has a background in both...

Bill Baton represents pharmaceutical companies in complex, often high-profile, patent litigation. Bill concentrates his practice in Hatch-Waxman ANDA litigation and protecting the intellectual property of branded pharmaceutical companies. He currently serves as New Jersey litigation counsel in more...

Eric Orlinsky co-chairs the firm's Corporate Practice and its Private Equity/Venture Capital subgroup and concentrates his practice in general business and securities law and counsels clients in private equity and venture capital investments, public and private offerings of debt and equity...

Greg Rapisarda is a passionate and prudent advocate who helps clients with legal advice on business and real estate development goals. Clients rely on Greg for day-to-day general counsel, specific advice on real estate development and land use legal matters, and problem solving to resolve disputes...

Counsel From the Earliest Stage of Development Through Disposition of Projects Throughout the continuum of financing, acquiring, developing, leasing and selling real estate are a multitude of complexities to address and challenges to overcome—from regulatory hurdles and shifting capital stacks to...

Intellectual property is often a company’s strongest asset, one that can be protected and leveraged to gain a competitive advantage. It is critical for companies of all sizes to effectively protect and enforce their intellectual property. Saul Ewing’s team of attorneys and patent agents with diverse...

Counsel From the Earliest Stage of Development Through Disposition of Projects Throughout the continuum of financing, acquiring, developing, leasing and selling real estate are a multitude of complexities to address and challenges to overcome—from regulatory hurdles and shifting capital stacks to...